Dr. Weeks’ Comment: My readers and patients have all heard me declare three things with regularity: 1) Cancer spreads by inflammation 2) the future of cancer treatment is using anti-inflammatory agents, and 3) most commercial anti-inflammatory agents are dangerous to the point of lethality if taken in overdosage. These topics are covered in this lecture. Over the past couple of years, conventional oncologists have begun to agree with me and it is common now for them to add Celebrex or other NSAIDs to the treatment protocol. What is the best anti-inflammatory agents which is safe and effective? Seed nutrition. Here is some new research which validates my opinion:
Regular Use of Aspirin and Other Non-Steroidal Anti-inflammatory Drugs and Breast Cancer Risk for Women at Familial or Genetic Risk
A Cohort Study
Rebecca D. Kehm; et al
Breast Cancer Res. 2019;21(52)
Abstract and Introduction
Background: The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced breast cancer risk, but it is not known if this association extends to women at familial or genetic risk. We examined the association between regular NSAID use and breast cancer risk using a large cohort of women selected for breast cancer family history, including 1054 BRCA1 or BRCA2 mutation carriers.
Results: From fully adjusted analyses, regular aspirin use was associated with a 39% and 37% reduced risk of breast cancer in the prospective (HR = 0.61; 95% CI = 0.33–1.14) and combined cohorts (HR = 0.63; 95% CI = 0.57–0.71), respectively. Regular use of COX-2 inhibitors was associated with a 61% and 71% reduced risk of breast cancer (prospective HR = 0.39; 95% CI = 0.15–0.97; combined HR = 0.29; 95% CI = 0.23–0.38). Other NSAIDs and acetaminophen were not associated with breast cancer risk in either cohort. Associations were not modified by familial risk, and consistent patterns were found by BRCA1 and BRCA2 carrier status, estrogen receptor status, and attained age.
Conclusion: Regular use of aspirin and COX-2 inhibitors might reduce breast cancer risk for women at familial or genetic risk.